Brief: Roivant Sciences Q1 Adjusted Net Income USD 57.49 Million Vs. IBES Estimate USD -208.4 Million
08/08/2024 12:00
Aug 08 (Reuters) - Roivant Sciences Q1 operating expenses USD 285.705 million. * Q1 net income USD 57.49 million * Q1 income from operations USD -120.186 million vs. IBES estimate USD -281.6 million * Q1 pretax profit USD 70.145 million vs. IBES estimate USD -227.7 million
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple